Cargando…

Targeting CD38 alleviates tumor-induced immunosuppression

Detalles Bibliográficos
Autores principales:	Tai, Yu-Tzu, Anderson, Kenneth C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762499/ https://www.ncbi.nlm.nih.gov/pubmed/29348814 http://dx.doi.org/10.18632/oncotarget.22992

Ejemplares similares

Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma
por: Bae, Jooeun, et al.
Publicado: (2021)

CD38 Correlates with an Immunosuppressive Treg Phenotype in Lupus-Prone Mice
por: Pérez-Lara, Jocelyn C., et al.
Publicado: (2021)

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1
por: Tai, Yu-Tzu, et al.
Publicado: (2018)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy
por: Moertel, Christopher L, et al.
Publicado: (2014)

Cutaneous bacteria induce immunosuppression
por: Skabytska, Yuliya, et al.
Publicado: (2015)

CD38-NAD(+)-Sirt1 axis in T cell immunotherapy
por: Chatterjee, Shilpak, et al.
Publicado: (2019)

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
por: Chemlal, Djamila, et al.
Publicado: (2023)

More insights into the immunosuppressive potential of tumor exosomes
por: Huber, Veronica, et al.
Publicado: (2008)

CD38 Deficiency Alleviates Diabetic Cardiomyopathy by Coordinately Inhibiting Pyroptosis and Apoptosis
por: Wang, Ling-Fang, et al.
Publicado: (2023)

Interleukin‐38 protects against sepsis by augmenting immunosuppressive activity of CD4(+)CD25(+) regulatory T cells
por: Ge, Yun, et al.
Publicado: (2019)

Targeting CD38 for acute leukemia
por: Zhong, Xushu, et al.
Publicado: (2022)

A Need for Targeted Immunosuppression after Lung Transplantation
por: Bharat, Ankit
Publicado: (2019)

CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond
por: Roccatello, Dario, et al.
Publicado: (2020)

CD38 Deficiency Alleviates D-Galactose-Induced Myocardial Cell Senescence Through NAD(+)/Sirt1 Signaling Pathway
por: Wang, Ling-Fang, et al.
Publicado: (2019)

Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer: combined targeting could improve outcomes
por: Terp, Mikkel G., et al.
Publicado: (2021)

CD200 promotes immunosuppression in the pancreatic tumor microenvironment
por: Choueiry, Fouad, et al.
Publicado: (2020)

Immunotherapeutic and Targeted Approaches in Multiple Myeloma
por: Nadeem, Omar, et al.
Publicado: (2020)

The Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy
por: Wo, Yu Jun, et al.
Publicado: (2019)

Phenotyping and Target Expression Profiling of CD34(+)/CD38(−) and CD34(+)/CD38(+) Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
por: Blatt, Katharina, et al.
Publicado: (2018)

Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment
por: Alexander, Eric T., et al.
Publicado: (2016)

Targeting Epigenetic Mechanisms to Alleviate Alcoholic Steatosis
por: Mandrekar, Pranoti
Publicado: (2020)

Immuno-targeting the multifunctional CD38 using nanobody
por: Li, Ting, et al.
Publicado: (2016)

Targeting CD38 in acute myeloid leukemia interferes with leukemia trafficking and induces phagocytosis
por: Farber, Meike, et al.
Publicado: (2021)

Nrf2 alleviates spaceflight-induced immunosuppression and thrombotic microangiopathy in mice
por: Shimizu, Ritsuko, et al.
Publicado: (2023)

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
por: Martin, Thomas G., et al.
Publicado: (2019)

Targeting CD38 in Neoplasms and Non-Cancer Diseases
por: Szlasa, Wojciech, et al.
Publicado: (2022)

Ultrasound-Targeted Microbubble Destruction Alleviates Immunosuppression Induced by CD71(+) Erythroid Progenitor Cells and Promotes PDL-1 Blockade Immunotherapy in the Lewis Lung Cancer Model
por: Tan, Xi, et al.
Publicado: (2021)

Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting
por: Viola, Domenico, et al.
Publicado: (2020)

CA125 effects on humoral immunosuppression
por: Kline, J. Bradford, et al.
Publicado: (2017)

Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
por: Fleming, Viktor, et al.
Publicado: (2018)

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
por: van de Donk, Niels W. C. J., et al.
Publicado: (2016)

Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38(+) tumors in mouse models in vivo
por: Fumey, William, et al.
Publicado: (2017)

Immunosuppression by viral N proteins
por: Chen, Jidang, et al.
Publicado: (2017)

Immunosuppressive therapy in dermatology and PML
por: Sterry, Wolfram, et al.
Publicado: (2009)

Immunosuppression via Tenascin-C
por: Bellone, Matteo, et al.
Publicado: (2015)

Modes of immunosuppression in glioblastoma microenvironment
por: Lehtipuro, Suvi, et al.
Publicado: (2019)

The paradox of immunosuppressants and COVID-19
por: Cheng, Guang-Shing, et al.
Publicado: (2022)

Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity
por: Pogue, Sarah L., et al.
Publicado: (2016)

APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications
por: Tai, Yu-Tzu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_os52juf51m0lbpgefurmba68b1